2020
Implications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography
Daubert MA, Sivak J, Dunning A, Douglas PS, Coyne B, Wang TY, Mark DB, Velazquez EJ. Implications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography. JAMA Internal Medicine 2020, 180: 494-502. PMID: 31985749, PMCID: PMC6990669, DOI: 10.1001/jamainternmed.2019.6958.Peer-Reviewed Original ResearchConceptsNormal stress echocardiographyComposite end pointStress echoExercise electrocardiographyStress echocardiographyMyocardial infarctionDownstream testingEnd pointDuke University Medical CenterExercise stress echoNegative exercise ECGStress ECG findingsAdverse cardiac eventsIncremental prognostic valueObservational cohort studyAdverse clinical eventsCoronary artery diseaseIndividual adverse eventsPopulation of patientsUniversity Medical CenterImaging resultsCoronary revascularizationAdverse eventsCardiac eventsCohort study
2010
Prevalence and predictors of mechanical dyssynchrony as defined by phase analysis in patients with left ventricular dysfunction undergoing gated SPECT myocardial perfusion imaging
Samad Z, Atchley AE, Trimble MA, Sun JL, Shaw LK, Pagnanelli R, Chen J, Garcia EV, Iskandrian AE, Velazquez EJ, Borges-Neto S. Prevalence and predictors of mechanical dyssynchrony as defined by phase analysis in patients with left ventricular dysfunction undergoing gated SPECT myocardial perfusion imaging. Journal Of Nuclear Cardiology 2010, 18: 24-30. PMID: 21082299, PMCID: PMC3077282, DOI: 10.1007/s12350-010-9310-7.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlgorithmsCardiac-Gated Single-Photon Emission Computer-Assisted TomographyFemaleHumansImage EnhancementImage Interpretation, Computer-AssistedIncidenceMaleMyocardial Perfusion ImagingNorth CarolinaPrevalenceReproducibility of ResultsRisk AssessmentRisk FactorsSensitivity and SpecificityVentricular Dysfunction, LeftConceptsLeft ventricular dysfunctionMechanical dyssynchronyVentricular dysfunctionIndependent predictorsBlack raceQRS durationPhase SDGated SPECT myocardial perfusionLeft ventricular ejection fractionTomography myocardial perfusion imagingStress scoresVentricular ejection fractionIschemic heart diseasePopulation of patientsMeasures of dyssynchronySPECT myocardial perfusionMyocardial perfusion imagingSingle photon emissionSignificant dyssynchronyEjection fractionEntire cohortUnivariate predictorsClinical variablesHeart diseaseMale gender
2007
Polymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy
Tang Z, Diamond MA, Chen J, Holly TA, Bonow RO, Dasgupta A, Hyslop T, Purzycki A, Wagner J, McNamara DM, Kukulski T, Wos S, Velazquez EJ, Ardlie K, Feldman AM. Polymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy. Clinical Pharmacology & Therapeutics 2007, 82: 435-440. PMID: 17728764, DOI: 10.1038/sj.clpt.6100331.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsBase SequenceCardiomyopathiesCase-Control StudiesDNA Mutational AnalysisGene FrequencyGenetic Predisposition to DiseaseHeart VentriclesHumansMolecular Sequence DataMutationMyocardial InfarctionMyocardial IschemiaPhenotypePolymorphism, Single NucleotideReceptor, Adenosine A1Receptor, Adenosine A2AReceptor, Adenosine A3Risk FactorsSeverity of Illness IndexVentricular Function, LeftConceptsIschemic cardiomyopathyInfarct sizeAdenosine receptor geneReceptor geneGenetic variantsPopulation of patientsVentricular functionVentricular sizeIschemic preconditioningNormal controlsHeart responseAdenosine receptorsCardiomyopathyIschemiaPatientsIndividual responsesDNA samplesResponsePolymorphismTherapyInjuryGenesVariants
2003
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal Of Medicine 2003, 349: 1893-1906. PMID: 14610160, DOI: 10.1056/nejmoa032292.Peer-Reviewed Original ResearchConceptsCaptopril groupValsartan groupMyocardial infarctionCardiovascular eventsAdverse eventsHeart failureMost drug-related adverse eventsDrug-related adverse eventsLeft ventricular systolic dysfunctionAngiotensin receptor blocker valsartanAngiotensin converting enzyme (ACE) inhibitorsEnd pointMyocardial Infarction ComplicatedNonfatal cardiovascular eventsDouble-blind trialPrimary end pointVentricular systolic dysfunctionComposite end pointLeft ventricular dysfunctionPopulation of patientsACE inhibitor captoprilAcute myocardial infarctionAdditional therapyCardiovascular morbidityRenal dysfunction